Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Medpace Holdings Inc's Business Segments
Medpace Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 707
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 707 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Metabolic31%
- Oncology29.6%
- Other13.9%
- Central Nervous System11.7%
- Cardiology8.5%
- Antiviral and Anti Infective5.3%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Metabolic | $ 219 | 31% |
| Oncology | $ 209 | 29.6% |
| Other | $ 98 | 13.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Medpace Holdings Inc dataset.
Description of Medpace Holdings Inc
Medpace Holdings Inc. is a global contract research organization (CRO) that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. Headquartered in Cincinnati, Ohio, the company was founded in 1992 by Dr. August Troendle, who still serves as its Chief Executive Officer.
Medpace offers a comprehensive range of clinical research services, including study design, protocol development, site identification and management, data management, biostatistics, regulatory affairs, clinical monitoring, medical writing, pharmacovigilance, and medical affairs. The company has specialized expertise in areas such as oncology, cardiology, neuroscience, infectious diseases, and rare diseases.
The company operates in over 45 countries and has a workforce of over 4,000 employees, including more than 1,200 medical personnel. Medpace has a proven track record of delivering high-quality clinical trials on time and within budget. As a result, it has established long-term partnerships with over 500 clients, ranging from small biotech startups to large pharmaceutical companies.
Medpace's quality management system is based on the principles of ICH Good Clinical Practice (GCP) and ISO 9001:2015. The company has been audited and inspected by regulatory authorities around the world, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Medpace went public in 2016, raising $172.5 million in its initial public offering (IPO) on the NASDAQ stock exchange. Since then, the company's stock has steadily grown, reflecting the company's strong financial performance and growth prospects.
In summary, Medpace Holdings Inc. is a leading global CRO that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. With a proven track record, specialized expertise, and a commitment to quality, Medpace is well-positioned to meet the increasing demand for clinical trial services in the healthcare industry.
Medpace offers a comprehensive range of clinical research services, including study design, protocol development, site identification and management, data management, biostatistics, regulatory affairs, clinical monitoring, medical writing, pharmacovigilance, and medical affairs. The company has specialized expertise in areas such as oncology, cardiology, neuroscience, infectious diseases, and rare diseases.
The company operates in over 45 countries and has a workforce of over 4,000 employees, including more than 1,200 medical personnel. Medpace has a proven track record of delivering high-quality clinical trials on time and within budget. As a result, it has established long-term partnerships with over 500 clients, ranging from small biotech startups to large pharmaceutical companies.
Medpace's quality management system is based on the principles of ICH Good Clinical Practice (GCP) and ISO 9001:2015. The company has been audited and inspected by regulatory authorities around the world, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Medpace went public in 2016, raising $172.5 million in its initial public offering (IPO) on the NASDAQ stock exchange. Since then, the company's stock has steadily grown, reflecting the company's strong financial performance and growth prospects.
In summary, Medpace Holdings Inc. is a leading global CRO that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. With a proven track record, specialized expertise, and a commitment to quality, Medpace is well-positioned to meet the increasing demand for clinical trial services in the healthcare industry.
Medpace Holdings Inc. is recognized as a prominent Contract Research Organization (CRO) that delivers a wide array of clinical research services tailored specifically for pharmaceutical and biotechnology companies on a global scale. The company stands out due to its therapeutic expertise, adaptable service delivery models, and rigorous scientific methodologies.
Segments
Medpace operates primarily through two distinct yet interrelated segments:
1. Clinical Development Services:
This segment encompasses comprehensive clinical development capabilities, allowing it to support clients at every stage of the drug development process. Key offerings within this segment include:
- Study Design: Customizing study protocols that adhere to regulatory standards and scientific principles.
- Protocol Development: Collaborating with clients to establish clear, compliant, and effective clinical protocols.
- Regulatory Affairs: Assisting clients in navigating the labyrinth of regulatory requirements, facilitating submissions to agencies like the FDA and EMA.
- Site Management: Overseeing the entire process of site selection, initiation, and day-to-day management to ensure smooth operation and compliance with Good Clinical Practice (GCP).
- Clinical Monitoring: Conducting regular assessments of data collection at clinical trial sites to maintain quality and compliance.
- Data Management: Including database design, data cleaning, and the implementation of quality control processes to ensure integrity and accuracy of clinical trial data.
- Statistical Analysis: Performing advanced statistical analyses to derive insights from trial data, ensuring that results are interpretable and actionable.
- Medical Writing: Preparing scientific documents, study reports, and regulatory filings to ensure clarity and compliance.
- Quality Assurance: Enforcing rigorous quality assurance practices across all processes to uphold high standards and regulatory compliance in clinical trials.
Medpace has extensive experience across diverse therapeutic areas, including oncology, neurology, cardiology, infectious diseases, and rare diseases, allowing for tailored approaches suited to the specific challenges and requirements of different fields.
2. Laboratory Services:
The laboratory services segment enhances Medpaces clinical capabilities by providing detailed biomarker testing and central laboratory services essential for clinical trials. Key components include:
- Biomarker Testing: Utilization of advanced techniques for genomic, proteomic, and immune assays to support the discovery of biomarkers integral for patient stratification and monitoring efficacy.
- Central Laboratory Services: In-house, state-of-the-art laboratory facilities equipped with cutting-edge technologies such as next-generation sequencing, flow cytometry, immunoassays, and multiplex assays to ensure quality and reliability in testing.
- Sample Management: Comprehensive handling of biological samples, including collection, processing, and storage, ensuring that samples are managed according to strict regulatory guidelines.
Products
Medpace does not engage in the development or manufacturing of proprietary products. Instead, it serves as a facilitator for pharmaceutical and biotechnology clients, aiding them in the development of their own products, including new drugs, medical devices, and diagnostic tools. The focus on collaboration ensures that services are aligned with client goals and regulatory requirements with the aim of achieving efficient and successful product development.
Services
Medpace’s clinical research services are diverse and tailored to meet the various needs of its clients. Here are some detailed offerings:
1. Study Design: Expertly crafting scientifically robust study designs that are not only innovative but also compliant with the necessary guidelines and regulatory standards.
2. Site Management: Ensuring effective site management involves meticulous selection and training of site personnel, monitoring site performance, and facilitating investigator meetings.
3. Data Management: The data management process includes creating databases tailored to trial needs, implementing data entry protocols, and executing ongoing data quality checks.
4. Statistical Analysis: Utilizing a team of experienced biostatisticians, Medpace performs a comprehensive set of statistical analyses, ensuring that the interpretation of data aligns with regulatory standards and scientific rigor.
5. Medical Writing: This service encompasses the full spectrum of regulatory documentation, including clinical study reports, investigator brochures, and publications, all crafted to meet the required statutory language and clarity.
6. Quality Assurance: This program includes routine inspections, audits, and ongoing training to uphold the highest levels of compliance and quality in every trial phase.
Conclusion
Medpace’s extensive and diversified service offerings, coupled with its unique therapeutic expertise, position it as a premier partner for pharmaceutical and biotechnology firms. With a comprehensive suite of clinical research services that address each phase of drug development, Medpace is committed to facilitating the successful market entry of new therapeutic solutions, enhancing patient care globally. The companys focus on quality, compliance, and collaboration ensures that it remains at the forefront of the clinical research landscape.
Segments
Medpace operates primarily through two distinct yet interrelated segments:
1. Clinical Development Services:
This segment encompasses comprehensive clinical development capabilities, allowing it to support clients at every stage of the drug development process. Key offerings within this segment include:
- Study Design: Customizing study protocols that adhere to regulatory standards and scientific principles.
- Protocol Development: Collaborating with clients to establish clear, compliant, and effective clinical protocols.
- Regulatory Affairs: Assisting clients in navigating the labyrinth of regulatory requirements, facilitating submissions to agencies like the FDA and EMA.
- Site Management: Overseeing the entire process of site selection, initiation, and day-to-day management to ensure smooth operation and compliance with Good Clinical Practice (GCP).
- Clinical Monitoring: Conducting regular assessments of data collection at clinical trial sites to maintain quality and compliance.
- Data Management: Including database design, data cleaning, and the implementation of quality control processes to ensure integrity and accuracy of clinical trial data.
- Statistical Analysis: Performing advanced statistical analyses to derive insights from trial data, ensuring that results are interpretable and actionable.
- Medical Writing: Preparing scientific documents, study reports, and regulatory filings to ensure clarity and compliance.
- Quality Assurance: Enforcing rigorous quality assurance practices across all processes to uphold high standards and regulatory compliance in clinical trials.
Medpace has extensive experience across diverse therapeutic areas, including oncology, neurology, cardiology, infectious diseases, and rare diseases, allowing for tailored approaches suited to the specific challenges and requirements of different fields.
2. Laboratory Services:
The laboratory services segment enhances Medpaces clinical capabilities by providing detailed biomarker testing and central laboratory services essential for clinical trials. Key components include:
- Biomarker Testing: Utilization of advanced techniques for genomic, proteomic, and immune assays to support the discovery of biomarkers integral for patient stratification and monitoring efficacy.
- Central Laboratory Services: In-house, state-of-the-art laboratory facilities equipped with cutting-edge technologies such as next-generation sequencing, flow cytometry, immunoassays, and multiplex assays to ensure quality and reliability in testing.
- Sample Management: Comprehensive handling of biological samples, including collection, processing, and storage, ensuring that samples are managed according to strict regulatory guidelines.
Products
Medpace does not engage in the development or manufacturing of proprietary products. Instead, it serves as a facilitator for pharmaceutical and biotechnology clients, aiding them in the development of their own products, including new drugs, medical devices, and diagnostic tools. The focus on collaboration ensures that services are aligned with client goals and regulatory requirements with the aim of achieving efficient and successful product development.
Services
Medpace’s clinical research services are diverse and tailored to meet the various needs of its clients. Here are some detailed offerings:
1. Study Design: Expertly crafting scientifically robust study designs that are not only innovative but also compliant with the necessary guidelines and regulatory standards.
2. Site Management: Ensuring effective site management involves meticulous selection and training of site personnel, monitoring site performance, and facilitating investigator meetings.
3. Data Management: The data management process includes creating databases tailored to trial needs, implementing data entry protocols, and executing ongoing data quality checks.
4. Statistical Analysis: Utilizing a team of experienced biostatisticians, Medpace performs a comprehensive set of statistical analyses, ensuring that the interpretation of data aligns with regulatory standards and scientific rigor.
5. Medical Writing: This service encompasses the full spectrum of regulatory documentation, including clinical study reports, investigator brochures, and publications, all crafted to meet the required statutory language and clarity.
6. Quality Assurance: This program includes routine inspections, audits, and ongoing training to uphold the highest levels of compliance and quality in every trial phase.
Conclusion
Medpace’s extensive and diversified service offerings, coupled with its unique therapeutic expertise, position it as a premier partner for pharmaceutical and biotechnology firms. With a comprehensive suite of clinical research services that address each phase of drug development, Medpace is committed to facilitating the successful market entry of new therapeutic solutions, enhancing patient care globally. The companys focus on quality, compliance, and collaboration ensures that it remains at the forefront of the clinical research landscape.